BRPF3: A Potential Drug Target and Biomarker (G27154)

Target Name: BRPF3

NCBI ID: G27154

BRPF3

BRPF3: A Potential Drug Target and Biomarker

BRPF3, or Bromodomain and PHD finger-containing protein 3, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, which consists of a catalytic domain and two N-terminal PHD fingers, has led to a high degree of structural flexibility, allowing it to interact with a wide range of molecules.

The discovery and characterization of BRPF3 began in the late 1990s, when researchers identified it as a protein that interacted with the protein p120GAP, which is a known regulator of protein tyrosination. This interaction led to the conclusion that BRPF3 might be involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

Since then, further studies have demonstrated that BRPF3 is involved in a wide range of cellular processes, including cell signaling, DNA replication, and metabolism. Its ability to interact with a wide range of molecules has led to the hypothesis that it could be a drug target for various diseases.

One of the key challenges in studying BRPF3 is its complex structure. Its N-terminal PHD fingers are known to be involved in the regulation of protein-protein interactions, but their precise functions and the mechanisms by which they interact with other molecules are not well understood.

In recent years, researchers have made significant progress in the study of BRPF3's functions, using a variety of techniques such as biochemical, cellular, and structural studies. These studies have led to a number of important findings, including the identification of BRPF3's role in the regulation of cell signaling pathways, such as the FAK/PI3K signaling pathway, which is involved in cell growth, differentiation, and survival.

Additionally, researchers have used cell-based assays to study the effects of small molecules on BRPF3's activity. These studies have led to the identification of a number of potential drug targets for BRPF3-related diseases, including neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The high degree of structural flexibility of BRPF3 also makes it an attractive candidate for drug development. By modifying its structure, researchers have been able to design small molecules that selectively interact with specific regions of the protein, allowing for more targeted and effective treatments.

In conclusion, BRPF3 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Its unique structure and complex functions make it an attractive candidate for drug development, and its role in the regulation of cellular processes is still being fully understood. Further research is needed to fully determine the mechanisms by which BRPF3 interacts with other molecules and to explore its potential as a drug target and biomarker.

Protein Name: Bromodomain And PHD Finger Containing 3

Functions: Scaffold subunit of various histone acetyltransferase (HAT) complexes, such as the MOZ/MORF and HBO1 complexes, which have a histone H3 acetyltransferase activity (PubMed:16387653, PubMed:26620551, PubMed:26677226). Plays a role in DNA replication initiation by directing KAT7/HBO1 specificity towards histone H3 'Lys-14' acetylation (H3K14ac), thereby facilitating the activation of replication origins (PubMed:26620551). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity (PubMed:16387653)

The "BRPF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRPF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets